Research at the UK DRI at UCL covers the journey from the person living with dementia to the laboratory and back again - with improved diagnosis and potential therapies put to the test.
From lab bench to bedside, and back again
UCL was selected as the hub of the UK DRI in 2016 because of its strength to bring together excellent clinical and basic neuroscience research to advance our understanding of neurodegeneration and identify novel targets and therapeutic approaches for dementia. As the hub, it has a larger research programme and also is the location for the national headquarters team who connect the whole institute together.
Research at the UK DRI at UCL covers the journey from the person living with dementia to the laboratory and back again - with improved diagnosis and potential therapies put to the test. The groups believe in intervening earlier in disease in order to change the trajectory.
We need to better understand the diversity and complexity of neurodegenerative diseases, like Alzheimer's disease, in order to understand the mechanisms involved, and ultimately how we can alter them to improve people's lives.
We must find treatments quicker, and that's why the UK DRI at UCL is taking a novel approach by integrating diverse expertise for efficiency, from genetics to diagnostics.
This work is enhanced by incredible clinical resources. Researchers have access to unique clinical cohorts, where comprehensive data has been collected throughout disease progression including memory assessments and brain tissue. The UK DRI at UCL provides a clinical arm to the whole of the UK DRI.
The future iconic home of the UK DRI at UCL will be alongside UCL's Queen Square Institute of Neurology in a new building on Gray's Inn Road.
Visit the UK DRI at UCL local website for up-to-date news.
UK DRI is seeking a Research Fellow to join the Wiseman Lab in Department of School of Life & Medical Sciences in UCL. We are looking for a highly motivated Research Fellow to undertake a proteomic-neuropathology project as part of an international collaborative project (Wiseman Lab, UCL, Ryan, Fox and Lashley, UCL, UK DRI Biomarkers Factory, Strydom Lab, KCL, and Poiter Lab, ICM, Paris). You will analyse amyloid-β proteomic data from cases of AD-AD and determine the relationship between a novel amyloid-β species and cerebral amyloid angiopathy (CAA) load, as well as test a newly developed anti-amyloid-β antibody for its specificity for cerebral amyloid angiopathy (CAA), in cases of DS-AD, FAD and sporadic EOAD. Also, you will coordinate this work with related work being undertaken in the group of Marie-Claude Potier (ICM, Paris), Andre Strydom (KCL) and the UK DRI Biomarkers Factory, in addition to communicating research findings to collaborative partners and study participants. You will have (or be close to obtaining) a PhD in Neuroscience or a cognate area, as well as experience in immunohistochemistry and immunofluorescence methods, including on human post-mortem brain material. Experience in applying specialist skills and techniques in a laboratory setting and an understanding of the legal requirements for working with human post-mortem tissue under UK law is also required for this role. Ref: B02-06151, Closing date: 10 December 2023Apply to centre